GNRH1 and ovarian hyperstimulation syndrome: This comparison is of clinical relevance in the current context, where the use of GnRH agonists as final oocyte maturation triggers has allowed for enhanced safety by drastically reducing the risk of OHSS, while enabling the targeting of more robust ovarian responses.